Vistagen Therapeutics Files 8-K on Leadership Changes
Ticker: VTGN · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, filing
Related Tickers: VTGN
TL;DR
Vistagen's leadership shuffled, new directors in, officers appointed, and comp plans updated.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the earliest event reported being June 23, 2025.
Why It Matters
This filing indicates significant changes in Vistagen's leadership and governance structure, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in board and officer composition can signal strategic shifts or internal challenges that may affect future performance.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- June 23, 2025 (date) — Earliest event reported
- June 25, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- 343 Allerton Ave. (address) — Principal executive offices
FAQ
Who departed from Vistagen Therapeutics' board or officer positions?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 23, 2025.
What is Vistagen Therapeutics' state of incorporation?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What is the principal executive office address for Vistagen Therapeutics?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California 94080.
What items are covered by this 8-K filing?
This 8-K covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Vistagen Therapeutics, Inc. (VTGN).